CHATHAM, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a ...

Details of the Poster Presentations. Poster Number: 750-P. Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose ...

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the presentation of key findings from the Phase III trial of Sodium Dichloroacetate (DCA) for Pyruvate ...

Poster Presentation Details : Presenter: Iredell Iglehart, M.D. Title: Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL1) Targets Non-restorative Sleep and ...

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform Provided by GlobeNewswire Jun 4, 2025, 11:00:00 AM ...

The poster presentations will be held on June 22, 2025, at the American Diabetes Association 85th Scientific Sessions in Chicago, IL. What is ACCG-2671 and its significance?

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin ...

Environmental Studies Thesis Poster Presentation. All Environmental Studies majors participate in public poster presentations as part of the thesis process. A poster session is organized for Wednesday ...

PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context” or "Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE”) ...

Poster Presentation Details: Title: A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced ...

Presentations should be no more than three minutes. The judges will have approximately five minutes to ask questions to learn more about the presenters’ projects and their challenges, solutions, ...